Brief Educational Video for Patients Prescribed LTBI Treatment
NCT05412212 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1898
Last updated 2025-09-09
Summary
Many patients who are prescribed treatment for latent tuberculosis (LTBI) do not complete treatment. Effective interventions that are low-cost and feasible for large-scale implementation are needed to support efforts to eliminate TB. The investigators hypothesize that a 3-minute educational LTBI video intervention will improve treatment completion compared to standard care (no intervention).
A randomized trial will be conducted at Kaiser Permanente Southern California, including adults who are prescribed treatment for LTBI, identified using an electronic health record algorithm. At the time of treatment prescription, patients will be randomized to receive the LTBI video intervention or standard care at a ratio of 2 to 1. Those in the intervention group will be sent a secure text message or e-mail with a link to the video. Individuals who watch the LTBI video will be invited to respond to 4 short questions about their perceptions of the video accessibility and content.
The primary outcome is LTBI treatment completion (dispensation of the required number of doses) in the year following prescription order. Secondary outcomes are LTBI treatment initiation (at least one dispensation) in the year following prescription order; initiation and completion within the year following prescription order stratified by LTBI treatment regimen (if feasible); the proportion of individuals randomized to the intervention group who watched the LTBI video; and the perceptions of those who watched the video.
The primary analysis will be based on intention-to-treat. Characteristics of individuals in the intervention and standard care groups will be described, and rates of LTBI treatment completion will be calculated. To assess the effect of the intervention, Poisson regression with robust standard errors will be used to estimate unadjusted and adjusted rate ratios and 95% confidence intervals. Per-protocol analyses will also be conducted, comparing those in the intervention group who watched the LTBI video to those in the standard care group. Similar methods will be used for secondary analyses.
Assuming the completion rate in the standard care group is 0.5 (based on recent KPSC data), approximately 918 patients will be needed to achieve 80% power with type one error 0.05 to detect an intervention effect of 0.10 in the completion rate between groups. This sample size will be feasible to achieve over the 1 year trial duration.
Conditions
- Latent Tuberculosis
Interventions
- OTHER
-
LTBI video intervention
3-minute educational video about latent tuberculosis and importance of taking and completing treatment
Sponsors & Collaborators
-
Kaiser Permanente
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-03
- Primary Completion
- 2024-12-29
- Completion
- 2025-12-31
Countries
- United States
Study Locations
More Related Trials
-
Treatment of Latent Tuberculosis Infection With Isoniazid
NCT00293228 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging
NCT02690818 ·Status: COMPLETED ·Phase: NA
-
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
NCT01398618 ·Status: UNKNOWN ·Phase: PHASE3
-
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
NCT00233168 ·Status: COMPLETED ·Phase: NA
-
Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation
NCT02231229 ·Status: COMPLETED ·Phase: PHASE4
-
TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment
NCT01549457 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
The Effect of Telephone Follow-up and Training on Treatment Adherence in Tuberculosis Patients and Contacts
NCT05202431 ·Status: COMPLETED ·Phase: NA
-
Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand
NCT02073240 ·Status: COMPLETED
-
Training Protocol on the Natural History of Tuberculosis
NCT01212003 ·Status: RECRUITING
-
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
NCT03988933 ·Status: COMPLETED ·Phase: PHASE2
-
"Conducting A Study On Video Observed Therapy In The Management Of Tuberculosis"
NCT05994144 ·Status: UNKNOWN ·Phase: NA
-
Using Biomarkers to Predict TB Treatment Duration
NCT02821832 ·Status: COMPLETED ·Phase: PHASE2
-
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
NCT05621343 ·Status: RECRUITING
-
Treatment of Latent TB Infection for Jailed Persons
NCT00128206 ·Status: COMPLETED ·Phase: PHASE3
-
The Treatment of Tuberculosis in HIV-Infected Patients
NCT00001033 ·Status: COMPLETED ·Phase: PHASE3
-
Latent Tuberculosis Infection in Bone Marrow Transplant Recipients
NCT01021124 ·Status: COMPLETED
-
Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy
NCT00811343 ·Status: COMPLETED ·Phase: NA
-
Pharmacist-Led Intervention to Improve TB Treatment Adherence
NCT06608069 ·Status: COMPLETED ·Phase: NA
-
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
NCT06022146 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
NCT05284812 ·Status: SUSPENDED ·Phase: PHASE2
-
Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
NCT02208427 ·Status: UNKNOWN ·Phase: PHASE3
-
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
NCT06050356 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Tuberculosis Prevention for HIV Infected Adults
NCT00057122 ·Status: COMPLETED ·Phase: PHASE3
-
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02606214 ·Status: TERMINATED ·Phase: PHASE1